
Jan 11 (Reuters) - Stoke Therapeutics Inc STOK.O:
STOKE THERAPEUTICS ANNOUNCES UPDATES TO TIMELINES FOR THE COMPLETION OF ENROLLMENT AND A PHASE 3 DATA READOUT FROM THE EMPEROR STUDY OF ZOREVUNERSEN FOR THE TREATMENT OF DRAVET SYNDROME
STOKE THERAPEUTICS INC: EXPECTS TO COMPLETE ENROLLMENT OF 150 PATIENTS IN Q2 2026, WITH A PHASE 3 DATA READOUT IN MID-2027
STOKE THERAPEUTICS INC - CONTINUES TO EXPLORE POTENTIAL FOR EXPEDITED DEVELOPMENT, REGISTRATION AND DELIVERY OF ZOREVUNERSEN TO PATIENTS